NCT06120530View on ClinicalTrials.gov

Intraperitoneal Bupivacaine for Pelvic Organ Prolapse

PHASE4CompletedINTERVENTIONAL
Enrollment

91

Participants

Timeline

Start Date

August 16, 2023

Primary Completion Date

March 15, 2024

Study Completion Date

March 15, 2024

Conditions
Pelvic Organ Prolapse
Interventions
DRUG

Bupivacaine

Intraperitoneal Bupivicaine without epinephrine 30 mg administered following completion of pelvic organ prolapse repair.

OTHER

Saline

Placebo

Trial Locations (1)

46032

IU north, Carmel

All Listed Sponsors
lead

Indiana University

OTHER